ABVC BIOPHARMA, INC.ABVCEarnings & Financial Report
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.
ABVC Q3 FY2025 Key Financial Metrics
Revenue
$796.0K
Gross Profit
$796.0K
Operating Profit
$-2.0M
Net Profit
$-2.0M
Gross Margin
100.0%
Operating Margin
-246.8%
Net Margin
-256.6%
YoY Growth
104.5%
EPS
$-0.09
ABVC BIOPHARMA, INC. Q3 FY2025 Financial Summary
ABVC BIOPHARMA, INC. reported revenue of $796.0K (up 104.5% YoY) for Q3 FY2025, with a net profit of $-2.0M (down 417.4% YoY) (-256.6% margin). Cost of goods sold was $0, operating expenses totaled $2.8M.
Key Financial Metrics
| Total Revenue | $796.0K |
|---|---|
| Net Profit | $-2.0M |
| Gross Margin | 100.0% |
| Operating Margin | -246.8% |
| Report Period | Q3 FY2025 |
ABVC BIOPHARMA, INC. Annual Revenue by Year
ABVC BIOPHARMA, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $509.6K).
ABVC BIOPHARMA, INC. Quarterly Revenue & Net Profit History
ABVC BIOPHARMA, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $796.0K | +104.5% | $-2.0M | -256.6% |
| Q4 FY2024 | $2.0K | -9.2% | N/A | N/A |
| Q3 FY2024 | $389.3K | +2350.7% | $-394.8K | -101.4% |
| Q2 FY2024 | $117.1K | +1817.5% | $-942.3K | -804.4% |
| Q1 FY2024 | $1.2K | -99.1% | $-2.8M | -235203.2% |
| Q4 FY2023 | $2.2K | -99.6% | N/A | N/A |
| Q3 FY2023 | $15.9K | -62.4% | $-3.3M | -20885.9% |
| Q2 FY2023 | $6.1K | -98.0% | $-2.3M | -37052.1% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6109 | $15884 | $2165 | $1205 | $117142 | $389276 | $1966 | $795950 |
| YoY Growth | -98.0% | -62.4% | -99.6% | -99.1% | 1817.5% | 2350.7% | -9.2% | 104.5% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.3M | $16.6M | $7.8M | $8.0M | $8.0M | $7.8M | $7.5M | $21.2M |
| Liabilities | $9.7M | $7.5M | $6.5M | $6.5M | $6.5M | $6.4M | $6.8M | $6.7M |
| Equity | $-379315 | $9.1M | $1.6M | $1.7M | $1.8M | $1.6M | $1.2M | $12.1M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-899827 | $-1.4M | $-4.2M | $-955816 | $-211425 | $60230 | $-1.8M | $-964710 |